{"id":"NCT00594165","sponsor":"UCB Pharma","briefTitle":"An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.","officialTitle":"An Open-Label Extension to the Double-Blind SP512 Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Early-Stage Idiopathic Parkinson's Disease.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-06","primaryCompletion":"2008-11","completion":"2008-11","firstPosted":"2008-01-15","resultsPosted":"2010-02-25","lastUpdate":"2014-10-02"},"enrollment":217,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Early-Stage Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Rotigotine","otherNames":["Neupro"]}],"arms":[{"label":"Rotigotine","type":"EXPERIMENTAL"}],"summary":"The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.","primaryOutcome":{"measure":"Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","timeFrame":"7 years","effectByArm":[{"arm":"Rotigotine","deltaMin":214,"sd":null}],"pValues":[]},"eligibility":{"minAge":"31 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":42,"countries":["United States","Canada"]},"refs":{"pmids":["22326237"],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":102,"n":216},"commonTop":["Somnolence","Oedema peripheral","Fall","Nausea","Dizziness"]}}